Allelic Combinations of Immune-Response Genes Associated with Glatiramer Acetate Treatment Response in Russian Multiple Sclerosis Patients
- 19 December 2011
- journal article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 13 (1) , 43-53
Abstract
Glatiramer acetate (GA) is widely used as a first-line disease-modifying treatment for multiple sclerosis (MS). However, a significant proportion of MS patient appears to experience modest benefit from GA-treatment. Genetic variants affecting the clinical response to GA are believed to be relevant as biomarkers of GA-treatment efficiency. Nine polymorphisms in candidate genes were analyzed as possible determinants of GA response in 285 Russian MS patients. Special attention was given to identification of response-associated allelic combinations by means of the APSampler algorithm. No significant associations were found for individual polymorphisms. Alleles DRB1*15, TGFB1*T, CCR5*d and IFNAR1*G were the components of the combinations, of which carriage was significantly higher in nonresponders than in responders. Carriers of the most significant combinations: DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G and DRB1*15 + TGFB1*T + CCR5*d (permutation p-values: 0.0056 and 0.013, respectively) had a 14 to 15-times increased risk of ineffective response to GA therapy. The results suggest that the influence of immune-response genes on GA-induced response has a polygenic nature. The data are interpreted as evidence of additive and epistatic influences of the genes on GA efficiency for MS treatment.Keywords
Funding Information
- Russian Foundation for Basic Research (08-04-01834a)
- Russian Foundation for Basic Research (11-04-01644-a)
- Russian Foundation for Basic Research (11-04-02016-a)
- European Community’s Seventh Framework Programme (FP7/2007-2013)
- European Community’s Seventh Framework Programme (N 212877)
- Johns Hopkins University Framework for the Future and NIH/NLM (LM008932)
This publication has 49 references indexed in Scilit:
- Linkage and association of proinflammatory cytokines genes IL-6, IFNG and TNF with multiple sclerosisMolecular Biology, 2010
- Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: Role of IGF-2Journal of Neuroimmunology, 2010
- Role of Type 1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in HumansClinical Cancer Research, 2010
- Genetic Polymorphisms, their Allele Combinations and IFN-β Treatment Response in Irish Multiple Sclerosis PatientsPharmacogenomics, 2009
- IL-17 and Th17 CellsAnnual Review of Immunology, 2009
- IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cellsNature Immunology, 2008
- Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent MechanismsImmunity, 2006
- A single nucleotide polymorphism in the first intron of the human IFN-γ gene:Human Immunology, 2000
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985